Search results for " Cost"

showing 10 items of 3966 documents

Computational fluid dynamics simulation to evaluate aortic coarctation gradient with contrast-enhanced CT

2014

Coarctation of aorta (CoA) is a narrowing of the aorta leading to a pressure gradient (Delta P) across the coarctation, increased afterload and reduced peripheral perfusion pressures. Indication to invasive treatment is based on values of maximal (systolic) trans-coarctation Delta P. A computational fluid dynamic (CFD) approach is herein presented for the non-invasive haemodynamic assessment of Delta P across CoA. Patient-specific CFD simulations were created from contrast-enhanced computed tomography (CT) and appropriate flow boundary conditions. Computed Delta P was validated with invasive intravascular trans-CoA pressure measurements. Haemodynamic indices, including pressure loss coeffic…

medicine.medical_specialtyBiomedical EngineeringHemodynamicsBioengineeringComputational fluid dynamicscontrast-enhanced computed tomographylaw.inventioncomputational fluid dynamicSettore ING-IND/14 - Progettazione Meccanica E Costruzione Di MacchineAfterloadlawmedicine.arteryInternal medicinemedicineShear stressPressure gradientPressure dropAortabusiness.industryChemistrycoarctation of aortapressure gradientGeneral MedicineComputer Science ApplicationsHuman-Computer InteractionPressure measurementCardiologybusinessComputer Methods in Biomechanics and Biomedical Engineering
researchProduct

Improving adherence in osteoporosis: a new management algorithm for the patient with osteoporosis

2011

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered…

medicine.medical_specialtyBone Density Conservation AgentBone densityOsteoporosisAlternative medicineadherence; osteoporosis; treatment algorithm; bone density; medication possession ratio; bisphosphonatesMedication AdherenceClinical ProtocolsCost of IllnessTreatment algorithmmedicineHumansBisphosphonatePharmacology (medical)DosingClinical ProtocolAdverse effectMED/01 - STATISTICA MEDICAOsteoporosis PostmenopausalAdherence bisphosphonates bone density medication possession ratio osteoporosis treatment algorithmMedication possession ratioPharmacologyBone Density Conservation Agentsbusiness.industryOsteoporosiGeneral Medicinemedicine.diseaseAlgorithmCost of IllneClinical trialBone Density Conservation AgentsTreatment OutcomeZoledronic acidAdherenceAdherence; Bisphosphonates; Bone density; Medication possession ratio; Osteoporosis; Treatment algorithm; Algorithms; Bone Density Conservation Agents; Clinical Protocols; Cost of Illness; Female; Humans; Osteoporosis; Osteoporosis Postmenopausal; Treatment Outcome; Medication Adherence; Pharmacology; Pharmacology (medical)Physical therapyOsteoporosisFemaleBone densitybusinessAlgorithmsHumanmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Cost Effectiveness of Peginterferon ??-2a Plus Ribavirin versus Interferon ??-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepati…

2004

Introduction: In adults with previously untreated chronic hepatitis C (CHC), the combination of peginterferon α-2a plus ribavirin produces a higher rate of sustained virological response (SVR) than interferon α-2b plus ribavirin, but it is still unproven whether this increase is cost effective. The objective of this study was to determine if the gain in SVR with peginterferon α-2a plus ribavirin is worth the incremental cost. Methods: We constructed a Markov model of disease progression in which cohorts of patients received peginterferon α-2a plus ribavirin or interferon α-2b plus ribavirin for 48 weeks (hepatitis C virus [HCV] genotype 1 and non-1 patients with fibrosis) or 24 weeks (genot…

medicine.medical_specialtyCirrhosisGenotypeCost effectivenessCost-Benefit AnalysisHepatitis C virusInterferon alpha-2medicine.disease_causeAntiviral AgentsSensitivity and SpecificityGastroenterologypeginterferon alpha2aPolyethylene Glycolschemistry.chemical_compoundchronic hepatitiInterferonInternal medicineRibavirinmedicineHumansRandomized Controlled Trials as Topicalpha2b interferonAntiviral AgentPharmacologybusiness.industryHealth PolicyRibavirinPublic Health Environmental and Occupational HealthInterferon-alphavirus diseasesHealth Care CostsHepatitis CHepatitis C Chronicmedicine.diseaseMarkov ChainsRecombinant Proteinsdigestive system diseasesModels EconomicTreatment OutcomechemistryImmunologyQuality of LifePeginterferon alfa-2bDrug Therapy CombinationbusinessPeginterferon alfa-2amedicine.drugPharmacoEconomics
researchProduct

Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Socie…

2020

This is a pre-copyedited, author-produced version of an article accepted for publication in European Journal of Preventive Cardiology following peer review. The version of record Piepoli, M.F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A.L. ... Tiberi, M. (2020). Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology*. European Journal of Preventive Cardiology (EJPC), 27(2), 181-205 is available online at: https://doi.org/10.1177/2047487319893035. European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regu…

medicine.medical_specialtyConsensusEpidemiologyCost effectivenessCost-Benefit AnalysisPopulationCardiologyPsychological interventionphysical activitypopulationGuidelinesrisk managementsmokingrehabilitationlipidsprimary carepreventionhealthy lifestyleInternal medicinePreventive Health ServicesEpidemiologyHumansMedicineguidelineseducationpsychosocial factorsstakeholderRisk managementeducation.field_of_studyVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801diabetesbusiness.industryStakeholderblood pressurerisk assessmentHealth Care CostsProtective FactorsPrognosisnutritionCardiovascular DiseasesHeart Disease Risk FactorsCardiologyPosition paperCardiology and Cardiovascular MedicinebusinessRisk assessmentclinical settings
researchProduct

Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation

2014

OBJECTIVE: We sought to evaluate the association between constipation severity, productivity losses and healthcare utilization in a national sample of Italian patients with chronic non-organic constipation (CC). METHODS: We enrolled 878 outpatients with CC. Clinical and demographic data were collected by physicians during clinical examinations. Patients completed a self-administered questionnaire (Patient Assessment of Constipation-Symptoms, PAC-SYM; Work Productivity and Activity Impairment; healthcare utilization, and Symptoms Checklist 90 Revised - Somatization Scale, SCL-90 R). RESULTS: Mean PAC-SYM score was 1.62 ± 0.69. Mean weekly sick time due to constipation was 2.7 ± 8.6 h and pro…

medicine.medical_specialtyConstipationChronic constipation; Cost-of-illness study; Direct cost; Functional constipation; Healthcare utilization; Indirect cost; Irritable bowel syndrome; Productivity loss; Oncology; Gastroenterologymacromolecular substancesIndirect costsdirect costMedicineIn patientIntensive care medicineProductivitycost-of-illness studyIrritable bowel syndromeirritable bowel syndromeChronic constipation; cost-of-illness study; direct cost; functional constipation; healthcare utilization; indirect cost; irritable bowel syndrome; productivity lossChronic constipationChronic constipationbusiness.industryGastroenterologyhealthcare utilizationfunctional constipationOriginal Articlesmedicine.diseaseproductivity lossOncologyHealthcare utilizationindirect costPhysical therapyFunctional constipationmedicine.symptombusinessUnited European Gastroenterology Journal
researchProduct

Cost-effectiveness and cost-utility analysis of the treatment of emotional disorders in primary care: psicap clinical trial. description of the sub-s…

2018

Introduction: In the primary care (PC) setting in Spain, the prevalence of emotional disorders (EDs) such as anxiety, depression and somatoform disorder is high. In PC patients, these disorders are not always managed in accordance with the recommendations provided by clinical practice guidelines, resulting in major direct and indirect economic costs and suboptimal treatment outcomes. The aim is to analyze and compare the cost-effectiveness and cost-utility of group-based psychological therapy versus treatment as usual (TAU). Methods: Multicenter, randomized controlled trial involving 300 patients recruited from PC centers in Madrid, Spain, with symptoms or possible diagnosis of anxiety, moo…

medicine.medical_specialtyCost effectivenesslcsh:BF1-990QALYslaw.inventionprimary care03 medical and health sciencesIndirect costs0302 clinical medicineRandomized controlled triallawmedicinePsychologyClinical Study Protocol030212 general & internal medicinecost-utilityGeneral PsychologyCost–utility analysisEmocionstransdiagnostic cognitive-behavioral therapy030227 psychiatryPatient Health QuestionnaireClinical triallcsh:PsychologyMoodemotional disordersPhysical therapyAnxietymedicine.symptomPsychology
researchProduct

Cost-effectiveness analysis of robot-assisted vs. open partial nephrectomy

2017

Background The cost-effectiveness of robot-assisted partial nephrectomy (RAPN) vs. the open procedure is not established. Methods We estimated in-hospital complications and the cost of RAPN vs. open partial nephrectomy (OPN) using an economic model. Costs incurred both intraoperatively and in hospital were considered. US data were extracted from existing literature. Results Mean in-hospital costs were $14,824 (95% CI $13,368-$16,898) for RAPN and $15,094 (95% CI $13,491-$17,140) for OPN. Complications after RAPN occurred in 23.3% (95% CI 20.0-25.8%) and after OPN in 36.1% (95% CI 35.6-36.6%) of the patients. In a sensitivity analysis, limited centre experience was associated with relevant i…

medicine.medical_specialtyCost-Benefit Analysismedicine.medical_treatment030232 urology & nephrologyBiophysicsNephrectomy03 medical and health sciencesPostoperative Complications0302 clinical medicineRobotic Surgical ProceduresmedicineHumansOpen partial nephrectomyHospital CostsComputer-assisted surgerybusiness.industryDecision TreesPerioperativeCost-effectiveness analysisNephrectomyComputer Science ApplicationsSurgeryModels EconomicTreatment Outcome030220 oncology & carcinogenesisSurgeryLower costbusinessThe International Journal of Medical Robotics and Computer Assisted Surgery
researchProduct

Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study.

2020

Objective: The objective of this study was to analyze health outcomes, resource utilization, and costs in osteoarthritis patients with chronic nociceptive pain who began treatment with an opioid in real-world practice in Spain. Methods: We designed a non-interventional, retrospective, longitudinal study with 36 months of follow-up using electronic medical records (EMRs) from primary care centers, of patients aged 18+ years who began a new treatment with an opioid drug in usual practice for chronic pain due to osteoarthritis. Health/non-health resource utilization and costs, treatment adherence, pain change, cognitive functioning, and dependence for basic activities of daily living (BADL) we…

medicine.medical_specialtyDiseases of the musculoskeletal systemOsteoarthritisHealth outcomescognitive deficit03 medical and health sciences0302 clinical medicineRheumatologymedicineOrthopedics and Sports MedicineIn patientpain030212 general & internal medicineCognitive deficitOriginal Research030203 arthritis & rheumatologybusiness.industrybasic activities of daily livingChronic painopioidshealthmedicine.diseasenon-health costshealth/non-health costsosteoarthritisNociceptionRC925-935OpioidPhysical therapymedicine.symptombusinessResource utilizationmedicine.drugTherapeutic advances in musculoskeletal disease
researchProduct

Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research

2017

Executive summary A concerted effort to tackle the global health problem posed by traumatic brain injury (TBI) is long overdue. TBI is a public health challenge of vast, but insufficiently recognised, proportions. Worldwide, more than 50 million people have a TBI each year, and it is estimated that about half the world’s population will have one or more TBIs over their lifetime. TBI is the leading cause of mortality in young adults and a major cause of death and disability across all ages in all countries, with a disproportionate burden of disability and death occurring in low-income and middle-income countries (LMICs). It has been estimated that TBI costs the global economy approximately $…

medicine.medical_specialtyEVIDENCE-BASED MEDICINETreatment outcomePoison controlOther Research Radboud Institute for Molecular Life Sciences [Radboudumc 0]EMERGENCY-DEPARTMENT VISITSReviewPLACEBO-CONTROLLED TRIALMiddle income countryHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciences0302 clinical medicineIntensive careBrain Injuries TraumaticJournal Articlemedicinetraumatic barin injuryHumans030212 general & internal medicineClinical careNeurologic diseasePsychiatryDIAGNOSTIC MANAGEMENT STRATEGIESbusiness.industryRANDOMIZED CONTROLLED-TRIALACUTE SUBDURAL-HEMATOMASEVERE HEAD-INJURYROAD TRAFFIC INJURIESbrain injuryHospital care3. Good healthReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Brain InjuriesHealth care costPATIENT-REPORTED OUTCOMESHuman medicineNeurology (clinical)businessHumanities030217 neurology & neurosurgeryGLASGOW COMA SCALE
researchProduct

Epidemiology and social costs of hip fracture.

2018

Hip fracture is an important and debilitating condition in older people, particularly in women. The epidemiological data varies between countries, but it is globally estimated that hip fractures will affect around 18% of women and 6% of men. Although the age-standardised incidence is gradually falling in many countries, this is far outweighed by the ageing of the population. Thus, the global number of hip fractures is expected to increase from 1.26 million in 1990 to 4.5 million by the year 2050. The direct costs associated with this condition are enormous since it requires a long period of hospitalisation and subsequent rehabilitation. Furthermore, hip fracture is associated with the devel…

medicine.medical_specialtyFinancing PersonalPopulationDisease03 medical and health sciencesIndirect costs0302 clinical medicineAge DistributionEpidemiologyMedicineHumans030212 general & internal medicineHospital CostseducationDepression (differential diagnoses)General Environmental Science030222 orthopedicseducation.field_of_studyHip fracturebusiness.industryHip FracturesIncidence (epidemiology)IncidenceLength of Staymedicine.diseaseHospitalizationSarcopeniaQuality of LifeGeneral Earth and Planetary SciencesbusinessHip fracture Social cost EpidemiologyDemographyInjury
researchProduct